CMRA
Price:
$0.0222
Market Cap:
$682.38K
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.[Read more]
Industry
Biotechnology
IPO Date
2020-12-21
Stock Exchange
NASDAQ
Ticker
CMRA
According to Comera Life Sciences Holdings, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.10. This represents a change of -88.86% compared to the average of -0.90 of the last 4 quarters.
The mean historical PE Ratio of Comera Life Sciences Holdings, Inc. over the last ten years is -43.19. The current -0.10 PE Ratio has changed -76.85% with respect to the historical average. Over the past ten years (40 quarters), CMRA's PE Ratio was at its highest in in the March 2023 quarter at -0.06. The PE Ratio was at its lowest in in the March 2021 quarter at -53.35.
Average
-43.19
Median
-36.54
Minimum
-92.50
Maximum
-0.53
Discovering the peaks and valleys of Comera Life Sciences Holdings, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual PE Ratio = -0.53
Minimum Annual Increase = -98.54%
Minimum Annual PE Ratio = -92.50
Year | PE Ratio | Change |
---|---|---|
2022 | -0.53 | -98.54% |
2021 | -36.54 | -60.49% |
The current PE Ratio of Comera Life Sciences Holdings, Inc. (CMRA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-43.19
5-year avg
-43.19
10-year avg
-43.19
Comera Life Sciences Holdings, Inc.’s PE Ratio is greater than SAB Biotherapeutics, Inc. (-0.65), greater than Processa Pharmaceuticals, Inc. (-0.37), greater than Fresh Tracks Therapeutics, Inc. (-0.78), greater than Third Harmonic Bio, Inc. (-26.95), greater than Indaptus Therapeutics, Inc. (-0.78), greater than Rezolute, Inc. (-3.80), greater than Tempest Therapeutics, Inc. (-0.88), greater than Forte Biosciences, Inc. (-0.39), greater than Genelux Corporation (-3.13), greater than Dyadic International, Inc. (-4.77), greater than Cingulate Inc. (-1.82), greater than Monopar Therapeutics Inc. (-1.18), greater than Shattuck Labs, Inc. (-2.08), greater than C4 Therapeutics, Inc. (-3.44), greater than Eliem Therapeutics, Inc. (-3.49), greater than Prelude Therapeutics Incorporated (-2.83), greater than Monte Rosa Therapeutics, Inc. (-3.11), greater than Virax Biolabs Group Limited (-1.34), greater than Blue Water Vaccines, Inc. (-0.17), less than Revelation Biosciences, Inc. (-0.09), less than Hillstream BioPharma, Inc. (-0.00), less than Kiora Pharmaceuticals, Inc. (4.61),
Company | PE Ratio | Market cap |
---|---|---|
-0.65 | $26.21M | |
-0.37 | $4.17M | |
-0.78 | $4.42M | |
-26.95 | $493.17M | |
-0.78 | $14.58M | |
-3.80 | $240.80M | |
-0.88 | $31.26M | |
-0.39 | $11.11M | |
-3.13 | $96.70M | |
-4.77 | $37.14M | |
-1.82 | $12.90M | |
-1.18 | $8.41M | |
-2.08 | $167.05M | |
-3.44 | $374.42M | |
-3.49 | $495.57M | |
-2.83 | $266.87M | |
-3.11 | $349.21M | |
-1.34 | $15.24M | |
-0.17 | $3.41M | |
-0.09 | $1.43M | |
-0.00 | $4.17M | |
4.61 | $10.52M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Comera Life Sciences Holdings, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Comera Life Sciences Holdings, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Comera Life Sciences Holdings, Inc.'s PE Ratio?
How is the PE Ratio calculated for Comera Life Sciences Holdings, Inc. (CMRA)?
What is the highest PE Ratio for Comera Life Sciences Holdings, Inc. (CMRA)?
What is the 3-year average PE Ratio for Comera Life Sciences Holdings, Inc. (CMRA)?
What is the 5-year average PE Ratio for Comera Life Sciences Holdings, Inc. (CMRA)?
How does the current PE Ratio for Comera Life Sciences Holdings, Inc. (CMRA) compare to its historical average?